Consequently, ongoing development of drugs for ER+ breast cancer has led to the development of third generation AIs, such as the non-steroidal agents Anastrazol and Letrozol and the steroidal agent Exemestane, which have increased efficacy compared to Tamoxifen in post-menopausal women [3]–[5]. Here, ESR1 is linked to breast cancer.